Lenalidomide Stada (Lenalidomide)

• Lenalidomide is used in hematologic malignancies that respond to immunomodulatory therapy.
• Multiple Myeloma: prolongs progression‑free survival and overall survival, and may deepen response when combined with dexamethasone in eligible patients.
• Myelodysplastic Syndromes with del(5q): reduces transfusion dependence, improves hemoglobin levels and platelet counts, and can lead to cytogenetic remission in appropriate patients.
• Mantle Cell Lymphoma: induces partial and complete responses, extends duration of remission, and is used after failure of prior chemo‑immunotherapy regimens.
• Maintenance Therapy in Multiple Myeloma: helps sustain remission after initial response and may delay disease progression when administered continuously.

• Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering substrate specificity. This leads to ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in reduced proliferation of malignant plasma cells, anti‑angiogenic effects, and modulation of immune cell activity, including enhanced T‑cell and natural killer cell function and contributes to tumor microenvironment alteration.

Lenalidomide may cause a range of adverse reactions, classified by frequency and severity.

Common Side Effects

• Neutropenia: decreased neutrophil count that can increase susceptibility to bacterial infections.
• Thrombocytopenia: reduced platelet levels that may cause easy bruising, petechiae or bleeding.
• Fatigue: persistent tiredness that can limit physical activity and affect quality of life.
• Gastrointestinal disturbances: nausea, diarrhea, constipation or abdominal discomfort that may require supportive care.

Serious or Rare Side Effects

• Venous thromboembolism: formation of deep‑vein thrombosis or pulmonary embolism, potentially life‑threatening.
• Severe skin reactions: rare events such as Stevens‑Johnson syndrome or toxic epidermal necrolysis requiring immediate discontinuation.
• Secondary malignancies: possible development of new cancers, including acute myeloid leukemia, during or after therapy.

Before initiating Lenalidomide therapy, several precautions should be observed to ensure patient safety.

• Pregnancy avoidance: contraindicated in pregnancy (Category X); effective contraception must be used for women of childbearing potential.
• Renal impairment: dose adjustment and close monitoring of renal function are required in patients with reduced kidney function.
• Hematologic monitoring: regular complete blood counts are essential to detect neutropenia or thrombocytopenia early.
• Thromboembolic risk: assess need for prophylactic anticoagulation, especially when combined with dexamethasone or other agents.
• Drug interactions: review concomitant medications for agents that may increase toxicity or reduce efficacy.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Lenalidomide interacts with several medicines; understanding the interaction level helps guide clinical decisions.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased bleeding risk; concurrent use should be avoided or closely monitored.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure and efficacy.
• Live vaccines: heightened risk of infection; vaccination should be avoided during treatment.
• Thalidomide: combined use increases risk of severe peripheral neuropathy and hematologic toxicity.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide plasma levels, requiring dose adjustment.
• NSAIDs or other myelosuppressive agents: additive bone‑marrow suppression may occur, necessitating frequent blood count monitoring.
• Antibiotics such as fluoroquinolones: potential QT prolongation when combined with other QT‑prolonging drugs.